Objective: To evaluate the efficacy and safety of tadalafil monotherapy for lower urinary tract symptoms secondary to benign prostatic hyperplasia (LUTS/BPH). Methods: A comprehensive search was done to identify randomized controlled trials comparing the efficacy and safety of tadalafil for LUTS/BPH with placebos. Meta-analytical techniques were applied to evaluate the differences in the study results. Results: Eight studies were identified and analyzed. Compared with placebo, tadalafil was associated with significant improvements in the International Prostate Symptom Score (IPSS) (mean difference = -2.19, p < 0.00001) and the International Index of Erectile Function (IIEF) score (mean difference = +4.66, p < 0.00001), despite the concomitant presence of erectile dysfunction. Significant differences were also observed in the IPSS irritative and obstructive subscores, IPSS quality of life index and BPH impact index. After pooling four doses (2.5, 5, 10 and 20 mg), tadalafil failed to produce a significant outcome in maximal urinary flow rate (Qmax) (mean difference = +0.26 ml/s, p = 0.14), but 5 mg of tadalafil significantly improved Qmax (mean difference = +0.63 ml/s, p = 0.04). No significant difference was detected in the incidence of serious adverse events (risk ratio = 1.00, p = 1.00) after tadalafil treatment. Conclusions: Tadalafil showed good efficacy and safety for improving LUTS and erectile dysfunction in men with BPH, and 5 mg of tadalafil significantly improved Qmax.

1.
Wei JT, Calhoun E, Jacobsen SJ: Urologic diseases in America project: benign prostatic hyperplasia. J Urol 2005;173:1256-1261.
[PubMed]
2.
Gacci M, Eardley I, Giuliano F, et al: Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2011;60:809-825.
[PubMed]
3.
McVary KT, Roehrborn CG, Avins AL, et al: Management of benign prostatic hyperplasia (BPH). American Urological Association website: http://www.auanet.org/content/guidelines-and-quality-care/clinical-guidelines.cfm?sub=bph (updated 2010).
4.
Rosen R, Altwein J, Boyle P, et al: Lower urinary tract symptoms and male sexual dysfunction: the multinational survey of the aging male (MSAM-7). Eur Urol 2003;44:637-649.
[PubMed]
5.
Rosen RC: Update on the relationship between sexual dysfunction and lower urinary tract symptoms/benign prostatic hyperplasia. Curr Opin Urol 2006;16:11-19.
[PubMed]
6.
Wang C: Phosphodiesterase-5 inhibitors and benign prostatic hyperplasia. Curr Opin Urol 2010;20:49-54.
[PubMed]
7.
Liu L, Zheng S, Han P, et al: Phosphodiesterase-5 inhibitors for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a systematic review and meta-analysis. Urology 2011;77:123-129.
[PubMed]
8.
Gacci M, Corona G, Salvi M, et al: A systematic review and meta-analysis on the use of phosphodiesterase 5 inhibitors alone or in combination with alpha-blockers for lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol 2012;61:994-1003.
[PubMed]
9.
Kedia GT, Uckert S, Jonas U, et al: The nitric oxide pathway in the human prostate: clinical implications in men with lower urinary tract symptoms. World J Urol 2008;26:603-609.
[PubMed]
10.
Uckert S, Hedlund P, Andersson KE, et al: Update on phosphodiesterase (PDE) isoenzymes as pharmacologic targets in urology: present and future. Eur Urol 2006;50:1194-1207.
[PubMed]
11.
Carson CC 3rd: Phosphodiesterase type 5 inhibitors: state of the therapeutic class. Urol Clin North Am 2007;34:507-515, vi.
[PubMed]
12.
Jadad AR, Moore RA, Carroll D, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
[PubMed]
13.
McVary KT, Roehrborn CG, Kaminetsky JC, et al: Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol 2007;177:1401-1407.
[PubMed]
14.
Roehrborn CG, McVary KT, Elion-Mboussa A, et al: Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a dose finding study. J Urol 2008;180:1228-1234.
[PubMed]
15.
Porst H, McVary KT, Montorsi F, et al: Effects of once-daily tadalafil on erectile function in men with erectile dysfunction and signs and symptoms of benign prostatic hyperplasia. Eur Urol 2009;56:727-735.
[PubMed]
16.
Dmochowski R, Roehrborn C, Klise S, et al: Urodynamic effects of once daily tadalafil in men with lower urinary tract symptoms secondary to clinical benign prostatic hyperplasia: a randomized, placebo controlled 12-week clinical trial. J Urol 2010;183:1092-1097.
[PubMed]
17.
Roehrborn CG, Kaminetsky JC, Auerbach SM, et al: Changes in peak urinary flow and voiding efficiency in men with signs and symptoms of benign prostatic hyperplasia during once daily tadalafil treatment. BJU Int 2010;105:502-507.
[PubMed]
18.
Kim SC, Park JK, Kim SW, et al: Tadalafil administered once daily for treatment of lower urinary tract symptoms in Korean men with benign prostatic hyperplasia: results from a placebo-controlled pilot study using tamsulosin as an active control. Low Urin Tract Symptoms 2011;3:86-93.
19.
Porst H, Kim ED, Casabe AR, et al: Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. Eur Urol 2011;60:1105-1113.
[PubMed]
20.
Egerdie RB, Auerbach S, Roehrborn CG, et al: Tadalafil 2.5 or 5 mg administered once daily for 12 weeks in men with both erectile dysfunction and signs and symptoms of benign prostatic hyperplasia: results of a randomized, placebo-controlled, double-blind study. J Sex Med 2012;9:271-281.
[PubMed]
21.
Oelke M, Giuliano F, Mirone V, et al: Monotherapy with tadalafil or tamsulosin similarly improved lower urinary tract symptoms suggestive of benign prostatic hyperplasia in an international, randomised, parallel, placebo-controlled clinical trial. Eur Urol 2012;61:917-925.
[PubMed]
22.
Wong P, Lawrentschuk N, Bolton DM: Phosphodiesterase 5 inhibitors in the management of benign prostatic hyperplasia and erectile dysfunction: the best of both worlds. Curr Opin Urol 2009;19:7-12.
[PubMed]
23.
Broderick GA, Brock GB, Roehrborn CG, et al: Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology 2010;75:1452-1458.
[PubMed]
24.
Filippi S, Morelli A, Sandner P, et al: Characterization and functional role of androgen-dependent PDE5 activity in the bladder. Endocrinology 2007;148:1019-1029.
[PubMed]
25.
Morelli A, Sarchielli E, Comeglio P, et al: Phosphodiesterase type 5 expression in human and rat lower urinary tract tissues and the effect of tadalafil on prostate gland oxygenation in spontaneously hypertensive rats. J Sex Med 2011;8:2746-2760.
[PubMed]
26.
Beamon CR, Mazar C, Salkini MW, et al: The effect of sildenafil citrate on bladder outlet obstruction: a mouse model. BJU Int 2009;104:252-256.
[PubMed]
27.
Gacci M, Del Popolo G, Macchiarella A, et al: Vardenafil improves urodynamic parameters in men with spinal cord injury: results from a single dose, pilot study. J Urol 2007;178:2040-2043; discussion 2044.
[PubMed]
28.
Donatucci CF, Brock GB, Goldfischer ER, et al: Tadalafil administered once daily for lower urinary tract symptoms secondary to benign prostatic hyperplasia: a 1-year, open-label extension study. BJU Int 2011;107:1110-1116.
[PubMed]
29.
Kang DH, Lee JY, Chung JH, et al: Comparison of efficacy for erectile function and lower urinary tract symptoms of tadalafil 20 mg on-demand and 5 mg once daily in patients with erectile dysfunction. Int J Clin Pract 2012;66:813-820.
[PubMed]
30.
Porst H, Rajfer J, Casabe A, et al: Long-term safety and efficacy of tadalafil 5 mg dosed once daily in men with erectile dysfunction. J Sex Med 2008;5:2160-2169.
[PubMed]
You do not currently have access to this content.